Spyre Therapeutics (SYRE) shares were down more than 13% in Wednesday trading after a regulatory filing showed that director Michael Thomas Henderson sold 20,000 company shares for $2 million on Monday.
Trading volume stood at more than 2.9 million shares against a daily average of about 1.3 million.
Price: $84.27, Change: $-12.78, Percent Change: -13.17%